Market Overview

Depomed Acquires US Rights to CAMBIA Migraine Medicine from Nautilus Neurosciences for $48.7M

Depomed (NASDAQ: DEPO) today announced that it has acquired the United States rights to CAMBIA® (diclofenac potassium for oral solution) from Nautilus Neurosciences for $48.7 million. In addition, Depomed may pay Nautilus up to an additional $5 million based on the achievement of certain annual net sales milestones. CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) indicated for acute treatment of migraine attacks with or without aura in adults 18 years of age or older.

See full press release

Posted-In: News Guidance Offerings FDA Management Global


Most Popular

Related Articles (DEPO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free